Issues
-
Cover Image
Cover Image
About the Cover
Infiltration by tumor-associated macrophages (TAMs) can promote the progression of cancer. It is thought that macrophages use a similar mode of migration as other leukocytes (i.e. amoeboid motility). However, the mechanism of macrophage migration in tumoral tissues has not been elucidated. Gui et al. determined that TAM migration differs from the migration patterns of other leukocytes, including other macrophage populations in nontumor tissues. TAMs use the protease-dependent mesenchymal mode to migrate into mouse and human tumor tissues. Inhibiting TAM migration without inhibiting macrophage migration in nontumor tissues reduces their accumulation in tumors and results in reduced tumor growth. This highlights how targeting the migration of detrimental cell types could be used to help in controlling tumor growth in cancer patients. Read more in this issue on page 1337. Original image from Figure 6C. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
What We’re Reading
In the Spotlight
Priority Brief
Research Articles
Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice
Fusobacterium nucleatum in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status
The Protease-Dependent Mesenchymal Migration of Tumor-Associated Macrophages as a Target in Cancer Immunotherapy
Cripto-1 Plasmid DNA Vaccination Targets Metastasis and Cancer Stem Cells in Murine Mammary Carcinoma
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.